EUVIMEDEUVIMED entdecken
Crossref

In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases

Christophe Le Terrier iD, Patrice Nordmann, Laurent Poirel iD

Journal of Antimicrobial Chemotherapy · 05.01.2023 · 78 (1) · 101-107

DOI: 10.1093/jac/dkac360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 29.10.2022. Verfasst von Christophe Le Terrier und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, University of Fribourg, Fribourg, Switzerland. Hauptthemen laut MEDLINE: Aztreonam, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: University of Fribourg, Swiss National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the in vitro activity of aztreonam in combination with novel β-lactamase inhibitors, namely avibactam, nacubactam, taniborbactam and zidebactam, against MDR MBL-producing Enterobacterales and Pseudomonas aeruginosa clinical isolates.

Methods

MIC values of aztreonam, aztreonam/β-lactam inhibitor but also cefiderocol as comparator were determined for 64 and 39 clinical Enterobacterales or P. aeruginosa isolates, respectively, producing representative MBLs, i.e. derivatives of NDM (n = 64), VIM (n = 32), IMP (n = 8) and SPM (n = 2). MICs were also determined for Escherichia coli TOP10 and P. aeruginosa PAO1 harbouring recombinant plasmids producing the different β-lactamases under isogenic backgrounds (n = 22 and n = 11, respectively). Fifty percent inhibitory concentrations were additionally determined for the abovementioned β-lactamase inhibitors using β-lactamase crude extracts.

Results

The susceptibility rate for aztreonam was 17.1% among MBL-producing Enterobacterales, while it was very high with aztreonam/zidebactam (98.4%), and to a lower extent with aztreonam/nacubactam (84.4%) and aztreonam/taniborbactam (75%), compared with aztreonam/avibactam (70.3%) and cefiderocol (39.1%). Among MBL-producing P. aeruginosa isolates, the susceptibility rates were 53.8% with aztreonam, 66.7% with aztreonam/nacubactam and aztreonam/taniborbactam combinations, and 69.2% with aztreonam/avibactam, aztreonam/zidebactam and cefiderocol.

Conclusions

Altogether, these results showed that combinations including aztreonam and novel β-lactamase inhibitors, such as zidebactam, nacubactam or taniborbactam, have a very significant in vitro activity against MDR MBL-producing Enterobacterales clinical isolates, the aztreonam/zidebactam combination being the best option. On the other hand, aztreonam/zidebactam is equivalent to aztreonam/avibactam and cefiderocol among MBL-producing P. aeruginosa isolates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aztreonambeta-Lactamase InhibitorsPseudomonas aeruginosaAnti-Bacterial Agentsbeta-LactamasesPseudomonasAzabicyclo CompoundsMicrobial Sensitivity TestsCefiderocolPiperidinesCyclooctanesLactamsBorinic AcidsCarboxylic Acids

Substanzen

Aztreonambeta-Lactamase InhibitorsAnti-Bacterial Agentsbeta-LactamasesAzabicyclo CompoundsCefiderocolzidebactamPiperidinesCyclooctanesnacubactam

Autor:innen und Institutionen

  • Department of Medicine, Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, University of Fribourg, Fribourg, Switzerland.
  • Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
  • Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
  • INSERM European Unit (LEA), IAME, Paris, France.
  • Institute for Microbiology, University of Lausanne and University Hospital Center, Lausanne, Switzerland.

ORCID-Profile: Christophe Le Terrier, Laurent Poirel

Förderung

  • University of Fribourg
  • Swiss National Science Foundation

Zitieren

APA

Le Terrier, C., Nordmann, P., & Poirel, L. (2023). In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases. Journal of Antimicrobial Chemotherapy, 78(1), 101-107. https://doi.org/10.1093/jac/dkac360

Vancouver

Le Terrier C, Nordmann P, Poirel L. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases. Journal of Antimicrobial Chemotherapy. 2023;78(1):101-107. doi:10.1093/jac/dkac360

BibTeX
@article{LeTerrier2023,
  author = {Le Terrier, Christophe and Nordmann, Patrice and Poirel, Laurent},
  title = {In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  volume = {78},
  number = {1},
  pages = {101--107},
  doi = {10.1093/jac/dkac360}
}
Kostenlos starten →